中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

28 records (took 0.014 seconds)

    CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR
    1.
    发明申请
    CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR 审中-公开
    选择性硒激酶抑制剂的控制释放药物组合物

    公开(公告)号：US20140010883A1

    公开(公告)日：2014-01-09

    申请号：US14005613

    申请日：2012-03-16

    Applicant: Harshal Jahagirdar ,  Ganesh Katkar ,  Satish Kumar Dalal ,  Shirishkumar Kulkarni

    Inventor： Harshal Jahagirdar ,  Ganesh Katkar ,  Satish Kumar Dalal ,  Shirishkumar Kulkarni

    IPC: A61K9/50 ,  A61K31/4525

    CPC classification number: A61K9/50 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2846 ,  A61K31/4525

    Abstract: The present invention provides a controlled release pharmaceutical composition comprising selective serotonin reuptake inhibitor and a process for preparation thereof. The controlled release pharmaceutical composition comprises: a deposit-core comprising a selective serotonin reuptake inhibitor, one or more controlled release agent(s) and one or more pharmaceutically acceptable excipient(s), a support-platform applied to the deposit-core, a controlled release coating and, an immediate release coating comprising a selective serotonin reuptake inhibitor and one or more pharmaceutically acceptable excipient(s).

    Abstract translation: 本发明提供一种包含选择性5-羟色胺再摄取抑制剂及其制备方法的控释药物组合物。 控释药物组合物包括：沉积物芯，其包含选择性5-羟色胺再摄取抑制剂，一种或多种控释剂和一种或多种药学上可接受的赋形剂，应用于沉积物核心的载体平台， 控制释放包衣和包含选择性5-羟色胺再摄取抑制剂和一种或多种药学上可接受的赋形剂的速释包衣。

    PROCESS FOR PREPARING PHARMACEUTICAL OPHTHALMIC COMPOSITIONS
    3.
    发明申请
    PROCESS FOR PREPARING PHARMACEUTICAL OPHTHALMIC COMPOSITIONS 有权
    制备药物组合物的方法

    公开(公告)号：US20120283252A1

    公开(公告)日：2012-11-08

    申请号：US13513335

    申请日：2010-12-02

    Applicant: Pravin Meghrajji Bhutada ,  Ashish Ashokrao Deshmukh ,  Sajeev Chandran ,  Shirishkumar Kulkarni

    Inventor： Pravin Meghrajji Bhutada ,  Ashish Ashokrao Deshmukh ,  Sajeev Chandran ,  Shirishkumar Kulkarni

    IPC: A61K31/542 ,  A61P27/02

    CPC classification number: A61K9/0048 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

    Abstract: Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry comprising a carbonic anhydrase inhibitor and a surfactant; b) preparing a polymer slurry comprising a polymer and water; c) preparing a solution comprising tonicity and preservative agents; d) mixing the polymer slurry of step b and the solution of step c, to form a vehicle concentrate and adjusting pH; e) adding the slurry of step a, to the vehicle concentrate of step d and mixing to homogenize; f) autoclaving the mixture of step e; g) sizing the mixture of step f, under aseptic condition.

    Abstract translation: 包含活性成分如碳酸酐酶抑制剂（CAI）或组合的药物眼用组合物和用于制备此类组合物的方法以及这些组合物在包括儿科人群的患者群体中的用途。 一种制备包含碳酸酐酶抑制剂的眼用组合物的方法，其包括：a）制备包含碳酸酐酶抑制剂和表面活性剂的浆液; b）制备包含聚合物和水的聚合物浆料; c）制备包含张力和防腐剂的溶液; d）将步骤b的聚合物浆料和步骤c的溶液混合，形成载体浓缩物并调节pH值; e）将步骤a的浆料加入到步骤d的车辆浓缩物中并混合均匀; f）高压灭菌步骤e的混合物; g）在无菌条件下调整步骤f的混合物的尺寸。

    PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN
    4.
    发明申请
    PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN 有权
    RIFAXIMIN的药物组合物

    公开(公告)号：US20090028940A1

    公开(公告)日：2009-01-29

    申请号：US12144453

    申请日：2008-06-23

    Applicant: Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    Inventor： Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    IPC: A61K9/22 ,  A61K31/439 ,  A61P1/12 ,  A61K9/20 ,  A61K9/00

    CPC classification number: A61K31/44 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/4808 ,  Y02A50/473 ,  Y02A50/475

    Abstract: A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.

    Abstract translation: 一种药物组合物，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或其多晶型物，药学上可接受的赋形剂和释放控制剂。 利福昔明的药物组合物包括：至少两个实体，其中一个实体是立即释放或快速释放，另一个实体是控制释放的。 多层片剂形式的药物组合物，包含至少一层，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映体或其多晶型物，药学上可接受的赋形剂; 所述层提供受控释放的利福昔明; 以及提供剂型在胃肠道中的延长停留时间的至少一个层。 包含具有体外溶出曲线的利福昔明的药物制剂，其中约70％的利福昔明在约24小时内释放。 所述组合物包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或多晶型物，一种或多种释放控制剂和引起致病根除的药学上可接受的赋形剂。

Patent Agency Ranking